Coronary Stenting plus Platelet Glycoprotein IIb/IIIa Blockade Compared with Tissue Plasminogen Activator in Acute Myocardial Infarction
Top Cited Papers
Open Access
- 10 August 2000
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 343 (6), 385-391
- https://doi.org/10.1056/nejm200008103430602
Abstract
Prevention of myocardial damage is the main goal of all reperfusion therapies in patients with acute myocardial infarction. The relative efficacy of various reperfusion strategies is under intensive investigation. We assessed whether coronary stenting combined with the blockade of platelet glycoprotein IIb/IIIa receptors produces a greater degree of myocardial salvage than fibrinolysis with an accelerated infusion of alteplase, a tissue plasminogen activator. A total of 140 patients were enrolled in the randomized trial; 71 were assigned to receive a stent plus abciximab, and 69 to receive intravenous alteplase. The primary end point was the degree of myocardial salvage, determined by means of serial scintigraphic studies with technetium Tc 99m sestamibi. The secondary end point was a composite of death, reinfarction, and stroke within six months after randomization. In the group that received a stent plus abciximab, the median size of the final infarct was 14.3 percent of the left ventricle (25th and 75th percentiles, 6.8 and 24.5 percent), as compared with a median of 19.4 percent (25th and 75th percentiles, 7.9 and 34.2 percent) in the alteplase group (P=0.02). This difference was due to the larger salvage index (the percentage of the left ventricle that was salvaged, divided by the percentage that was compromised by the initial perfusion defect) in the stent group: 0.57 (25th and 75th percentiles, 0.35 and 0.69), as compared with 0.26 (25th and 75th percentiles, 0.09 and 0.61; P<0.001). The cumulative incidence of death, reinfarction, or stroke at six months was lower in the stent group than in the alteplase group (8.5 vs. 23.2 percent, P=0.02; relative risk, 0.34; 95 percent confidence interval, 0.13 to 0.88). In patients with acute myocardial infarction, coronary stenting plus abciximab leads to a greater degree of myocardial salvage and a better clinical outcome than does fibrinolysis with a tissue plasminogen activator.Keywords
This publication has 32 references indexed in Scilit:
- Long-Term Benefit of Primary Angioplasty as Compared with Thrombolytic Therapy for Acute Myocardial InfarctionNew England Journal of Medicine, 1999
- Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa ReceptorsNew England Journal of Medicine, 1999
- Long-term outcome after primary angioplasty: report from the Primary Angioplasty in Myocardial Infarction (PAMI-I) trialJournal of the American College of Cardiology, 1999
- Clinical Experience With Primary Percutaneous Transluminal Coronary Angioplasty Compared With Alteplase (Recombinant Tissue-Type Plasminogen Activator) in Patients With Acute Myocardial InfarctionJournal of the American College of Cardiology, 1998
- A Clinical Trial Comparing Primary Coronary Angioplasty with Tissue Plasminogen Activator for Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- A Comparison of Thrombolytic Therapy with Primary Coronary Angioplasty for Acute Myocardial InfarctionNew England Journal of Medicine, 1996
- Immediate Angioplasty Compared with the Administration of a Thrombolytic Agent Followed by Conservative Treatment for Myocardial InfarctionNew England Journal of Medicine, 1993
- A Comparison of Immediate Coronary Angioplasty with Intravenous Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?Circulation, 1989